Scribe—one of a new wave of gene editing biotech companies—focuses on developing CRISPR-based treatments through its genetic modification platform, designed to build and apply its suite of CRISPR technologies designed for therapeutic use . . .
- CRISPR
- Genome Editing
- CRISPR-Cas9
- Drug Discovery
- Drug Delivery
- Financing
- GEN Edge
- Magazine
- May 2021 Vol. 41 No. 5
Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B
[L.-R.] Scribe Therapeutics co-founders Benjamin L. Oakes, PhD, president and CEO, and Brett T. Staahl, PhD, VP of platform; Chief Business Officer Svetlana Lucas, PhD; Nobel laureate Jennifer A. Doudna, PhD, and David F. Savage, PhD, who are also co-founders as well as scientific advisors. [Scribe Therapeutics]
